Literature DB >> 2172779

Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs.

A E Cribb1, M Miller, A Tesoro, S P Spielberg.   

Abstract

The hydroxylamine and nitroso metabolites formed by N4-oxidation of sulfonamides are thought to be involved in the pathogenesis of idiosyncratic reactions to this class of drugs. Idiosyncratic reactions to sulfonamides are characterized by multisystemic toxicity, including hepatitis, nephritis, dermatitis, and blood dyscrasias (aplastic anemia, agranulocytosis). We have previously shown that cytochrome P-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite. In this paper we report the N4-oxidation of sulfamethoxazole by activated monocytes and neutrophils (human and canine) to form sulfamethoxazole hydroxylamine and nitrosulfamethoxazole. The presumed nitroso intermediate was not detected. Purified myeloperoxidase and prostaglandin H synthase were also capable of mediating the oxidation of sulfamethoxazole. The present studies suggest that myeloperoxidase is responsible for the observed oxidation by phagocytic cells. Oxidation by neutrophils may play a role in agranulocytosis, and oxidation by monocytes may facilitate antigen presentation. Extrahepatic bioactivation of sulfonamides by peroxidases in phagocytic cells and other tissues may be important in determining the range of adverse reactions to sulfonamides that occur.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172779

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 2.  Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis.

Authors:  J P Uetrecht
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

Review 3.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

Review 4.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

5.  Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells.

Authors:  C Burkhart; S von Greyerz; J P Depta; D J Naisbitt; M Britschgi; K B Park; W J Pichler
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

6.  Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Authors:  J Funk-Keenan; J Sacco; Y Y Amos Wong; S Rasmussen; A Motsinger-Reif; L A Trepanier
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

7.  Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity.

Authors:  D J Naisbitt; S J Hough; H J Gill; M Pirmohamed; N R Kitteringham; B K Park
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

8.  Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.

Authors:  James C Sacco; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

9.  Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Authors:  Hideaki Kagaya; Masatomo Miura; Takenori Niioka; Mitsuru Saito; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

10.  "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.

Authors:  S N Lavergne; H Wang; H E Callan; B K Park; D J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2009-08-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.